Overview

Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
A new inactivated polio vaccine based on attenuated poliovirus strains was developed to transfer the technology to manufacturers in low- and middle-income countries. This vaccine was produced in different dosages and in different formulations. In healthy adults the safety of the highest dose was comparable to that of the existing inactivated polio vaccine. The purpose of this trial is to determine the safety of the different dosages and formulations of the vaccine in infants. The second goal of this study is to analyse the immune response after three doses in infants.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pauline Verdijk
Collaborator:
World Health Organization
Treatments:
Aluminum Hydroxide
Vaccines